Navigation Links
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
Date:6/3/2009

- Improvement Was Noted At Day 3 And All Subsequent Study Visits -

FORT LEE, N.J., June 3 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical Psychiatry. This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy assessments at all study visits starting at day 3. In addition, lurasidone was generally well-tolerated and was associated with weight and metabolic changes that were similar to placebo. The study is available at www.psychiatrist.com.

"We are pleased to see the first publication reporting results of a lurasidone placebo-controlled trial in the treatment of patients with acute schizophrenia," said Antony Loebel, M.D., senior author and vice president of clinical research, Dainippon Sumitomo Pharma America, Inc. "Findings from this phase 2 study are consistent with data emerging from the lurasidone global development program, including a recently completed, large phase 3 placebo-controlled trial."

The primary efficacy measure was the BPRSd (Brief Psychiatric Rating Scale-derived). Lurasidone demonstrated significant improvement at Week 6 (LOCF endpoint) compared to placebo on the BPRSd (-8.9 vs. -4.2; p=0.012), as well as on all secondary efficacy measures, including the PANSS (Positive and Negative Syndrome Scale) total score (-14.1 vs. -5.5; p=0.004), PANSS positive subscale (-4.3 vs. -1.7; p=0.006), PANSS negative subscale (-2.9 vs. -1.3; p=0.025) and CGI-S (Clinical Global Impressions-Se
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
2. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
9. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer
11. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
(Date:7/31/2015)... -- According to a new market research report ... Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables ... Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment Market ... at a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
(Date:7/31/2015)... , ... July 31, 2015 , ... Transfinder, a software ... , Total sales were up 16 percent year-over-year for the first six months ended ... Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just ... industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at ... attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... research firm, has been recognized in the 2015 Aster Awards national competition for ... healthcare organization serving Ocean City and surrounding communities in Coastal Maryland and Southern ...
(Date:7/31/2015)... ... , ... The 2015 ALS Ice Bucket Challenge will officially get underway today ... honor Ice Bucket co-founders Pat Quinn and Pete Frates, the ALS community and Lou ... among the ALS organizations to find treatments and cures for the disease. , ...
(Date:7/31/2015)... ... , ... Like nearly every other form of surgery, it shouldn't come as ... and less intrusive and painful. Leading these advances in the United States has ... stands as the only doctor in the United States who is qualified to practice, ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2
... A group of researchers from Stanford have identified the nitric ... chemical events gradually resulting in the development of an embryo.He ... the sperm.// ,The research is based on the ... purple invertebrates found in the Pacific Ocean just a few ...
... flowing smoothly after angioplasty shows surprising success in early testing. ... the drug-coated stent. //In testing on 50 patients over 3 ... ,More than 2 million Americans undergo angioplasty annually, ... most of them if these promising results hold up in ...
... honey could prove effective in arresting the dental plaque ... New Zealand researcher will report at the American Association// ... enzyme in honey that produces hydrogen peroxide is the ... Dr. Peter C. Molan, associate professor of biochemistry at ...
... of Medicine have recently found that the brain's 'nose plug' ... stop smelling something, even though the odour is still there.// ... journal Science show that a protein called CNGA4 helps plug ... neurons is to detect smells and send that information to ...
... close to signing a deal to acquire the 51.5 per ... drugmaker Abbott Laboratories Inc. An industry source who declined to ... next few days to buy the stake in Abbott Laboratories ... officials from the company’s regional office in singapore will be ...
... heart surgery for patients in their mid-eighties and beyond ... for the elderly.// ,According to Dr. Todd Rosengart, ... heart surgery, if indicated, is safe and will improve ... of cardiac surgery at Southeastern Healthcare in Illinois. ...
Cached Medicine News:Health News:The route to fertilization, 2Health News:Heart Surgery Is Getting Safer for the Old 2
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
Medicine Products: